Skip to main content
SpringerLink
Log in

Antibody-Mediated Rejection

  • Chapter
  • First Online:
Heart Failure

  • 4764 Accesses

Abstract

Antibody-mediated rejection (AMR) of the cardiac allograft, formerly also termed vascular or humoral rejection, typically occurs in the absence of interstitial lymphocytic infiltrates that are characteristic of acute cellular rejection. Its pathological hallmarks include capillary endothelial activation and macrophage infiltration, as well as vascular immunofluorescent deposition of immunoglobulin and complement. Clinically, AMR occurs early post heart transplant and tends to recur, is harder to treat, and is associated with poor outcomes [1–6].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Notes

  1. 1.

    All recommendations are Level of Evidence C.

References

  1. Hammond EH, Yowell RL, Nunoda S, Menlove RL, Renlund DG, Bristow MR, et al. Vascular (humoral) rejection in heart transplantation: pathologic observations and clinical implications. J Heart Transplan. 1989;8(6):430–43.

    CAS  Google Scholar 

  2. Lones MA, Czer LS, Trento A, Harasty D, Miller JM, Fishbein MC. Clinical-pathologic features of humoral rejection in cardiac allografts: a study in 81 consecutive patients. J Heart Lung Transplant. 1995;14(1 Pt 1):151–62.

    CAS  PubMed  Google Scholar 

  3. Michaels PJ, Espejo ML, Kobashigawa J, Alejos JC, Burch C, Takemoto S, et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant. 2003;22(1):58–69.

    Article  PubMed  Google Scholar 

  4. Casarez TW, Perens G, Williams RJ, Kutay E, Fishbein MC, Reed EF, et al. Humoral rejection in pediatric orthotopic heart transplantation. J Heart Lung Transplant. 2007;26(2):114–9.

    Article  PubMed  Google Scholar 

  5. Everitt MD, Hammond ME, Snow GL, Stehlik J, Revelo MP, Miller DV, et al. Biopsy-diagnosed antibody-mediated rejection based on the proposed International Society for Heart and Lung Transplantation working formulation is associated with adverse cardiovascular outcomes after pediatric heart transplant. J Heart Lung Transplant. 2012;31(7):686–93.

    Article  PubMed  Google Scholar 

  6. Ensley RD, Hammond EH, Renlund DG, Yowell RL, Bristow MR, DeWitt CW, et al. Clinical manifestations of vascular rejection in cardiac transplantation. Transplant Proc. 1991;23(1 Pt 2):1130–2.

    CAS  PubMed  Google Scholar 

  7. Cherry R, Nielsen H, Reed E, Reemtsma K, Suciu-Foca N, Marboe CC. Vascular (humoral) rejection in human cardiac allograft biopsies: relation to circulating anti-HLA antibodies. J Heart Lung Transplant 1992;11(1 Pt 1):24–9; discussion 30.

    Google Scholar 

  8. Reed EF, Demetris AJ, Hammond E, Itescu S, Kobashigawa JA, Reinsmoen NL, et al. Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant. 2006;25(2):153–9.

    Article  PubMed  Google Scholar 

  9. Tambur AR, Pamboukian SV, Costanzo MR, Herrera ND, Dunlap S, Montpetit M, et al. The presence of HLA-directed antibodies after heart transplantation is associated with poor allograft outcome. Transplantation. 2005;80(8):1019–25.

    Article  PubMed  Google Scholar 

  10. Michaels PJ, Fishbein MC, Colvin RB. Humoral rejection of human organ transplants. Springer Semin Immunopathol. 2003;25(2):119–40.

    Article  PubMed  Google Scholar 

  11. Wasowska BA. Mechanisms involved in antibody- and complement-mediated allograft rejection. Immunol Res. 2010;47(1–3):25–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Loy TS, Bulatao IS, Darkow GV, Demmy TL, Reddy HK, Curtis J, et al. Immunostaining of cardiac biopsy specimens in the diagnosis of acute vascular (humoral) rejection: a control study. J Heart Lung Transplant. 1993;12(5):736–40.

    CAS  PubMed  Google Scholar 

  13. Olsen SL, Wagoner LE, Hammond EH, Taylor DO, Yowell RL, Ensley RD, et al. Vascular rejection in heart transplantation: clinical correlation, treatment options, and future considerations. J Heart Lung Transplant. 1993;12(2):S135–42.

    CAS  PubMed  Google Scholar 

  14. Miller LW, Wesp A, Jennison SH, Graham MA, Martin TW, McBride LR, et al. Vascular rejection in heart transplant recipients. J Heart Lung Transplant. 1993;12(2):S147–52.

    CAS  PubMed  Google Scholar 

  15. Kobashigawa J, Crespo-Leiro MG, Ensminger SM, Reichenspurner H, Angelini A, Berry G, et al. Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant. 2011;30(3):252–69.

    Article  PubMed  Google Scholar 

  16. Berry GJ, Burke MM, Andersen C, Bruneval P, Fedrigo M, Fishbein MC, et al. The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. J Heart Lung Transplant. 2013;32(12):1147–62.

    Article  PubMed  Google Scholar 

  17. Kfoury AG, Stehlik J, Renlund DG, Snow G, Seaman JT, Gilbert EM, et al. Impact of repetitive episodes of antibody-mediated or cellular rejection on cardiovascular mortality in cardiac transplant recipients: defining rejection patterns. J Heart Lung Transplant. 2006;25(11):1277–82.

    Article  PubMed  Google Scholar 

  18. Wu GW, Kobashigawa JA, Fishbein MC, Patel JK, Kittleson MM, Reed EF, et al. Asymptomatic antibody-mediated rejection after heart transplantation predicts poor outcomes. J Heart Lung Transplant. 2009;28(5):417–22.

    Article  PubMed  Google Scholar 

  19. Reinsmoen NL, Patel J, Mirocha J, Lai CH, Naim M, Ong G, et al.. Optimizing transplantation of sensitized heart candidates using 4 antibody detection assays to prioritize the assignment of unacceptable antigens. J Heart Lung Transplant 2016;35(2):165–172. PubMed PMID: 26683810.

    Google Scholar 

  20. Eckels DD, Stehlik J, Kfoury AG. The detection and role of circulating antibodies in rejection. Curr Opin Organ Transplant. 2013;18(5):589–94.

    Article  CAS  PubMed  Google Scholar 

  21. Toyoda M, Petrosian A, Jordan SC. Immunological characterization of anti-endothelial cell antibodies induced by cytomegalovirus infection. Transplantation. 1999;68(9):1311–8.

    Article  CAS  PubMed  Google Scholar 

  22. George I, Colley P, Russo MJ, Martens TP, Burke E, Oz MC, et al. Association of device surface and biomaterials with immunologic sensitization after mechanical support. J Thorac Cardiovasc Surg. 2008;135(6):1372–9.

    Article  PubMed  Google Scholar 

  23. Bull DA, Reid BB, Selzman CH, Mesley R, Drakos S, Clayson S, et al. The impact of bridge-to-transplant ventricular assist device support on survival after cardiac transplantation. J Thorac Cardiovasc Surg. 2010;140(1):169–73.

    Article  PubMed  Google Scholar 

  24. Moazami N, Itescu S, Williams MR, Argenziano M, Weinberg A, Oz MC. Platelet transfusions are associated with the development of anti-major histocompatibility complex class I antibodies in patients with left ventricular assist support. J Heart Lung Transplant. 1998;17(9):876–80.

    CAS  PubMed  Google Scholar 

  25. McCarthy JF, Cook DJ, Smedira NG, O’Malley KJ, Massad MG, Sano Y, et al. Vascular rejection in cardiac transplantation. Transplant Proc. 1999;31(1–2):160.

    Article  CAS  PubMed  Google Scholar 

  26. Greger B, Grossmann T, Gartner HV, Hopt UT, Lauchart W. Positive postoperative donor-specific crossmatch correlates with B-cell infiltration and poor graft prognosis. Transplant Proc. 1990;22(4):1900–2.

    CAS  PubMed  Google Scholar 

  27. Ioannou A, Dalle Lucca J, Tsokos GC. Immunopathogenesis of ischemia/reperfusion-associated tissue damage. Clin Immunol. 2011;141(1):3–14.

    Article  CAS  PubMed  Google Scholar 

  28. Land WG. Emerging role of innate immunity in organ transplantation part II: potential of damage-associated molecular patterns to generate immunostimulatory dendritic cells. Transplant Rev (Orlando). 2012;26(2):73–87.

    Article  Google Scholar 

  29. Stewart S, Winters GL, Fishbein MC, Tazelaar HD, Kobashigawa J, Abrams J, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant. 2005;24(11):1710–20.

    Article  PubMed  Google Scholar 

  30. Singhal AK, Drakos SG, Kfoury AG, Horne BD, Verma DR, Stehlik J. Prolonged allograft ischemic time is not associated with higher incidence of antibody-mediated rejection. J Heart Lung Transplant. 2010;29(10):1198–200.

    Article  PubMed  Google Scholar 

  31. Hammond EH, Wittwer CT, Greenwood J, Knape WA, Yowell RL, Menlove RL, et al. Relationship of OKT3 sensitization and vascular rejection in cardiac transplant patients receiving OKT3 rejection prophylaxis. Transplantation. 1990;50(5):776–82.

    Article  CAS  PubMed  Google Scholar 

  32. Hammond EH, Hansen JK, Spencer LS, Jensen A, Yowell RL. Immunofluorescence of endomyocardial biopsy specimens: methods and interpretation. J Heart Lung Transplant. 1993;12(2):S113–24.

    CAS  PubMed  Google Scholar 

  33. Keenan RJ, Lega ME, Dummer JS, Paradis IL, Dauber JH, Rabinowich H, et al. Cytomegalovirus serologic status and postoperative infection correlated with risk of developing chronic rejection after pulmonary transplantation. Transplantation. 1991;51(2):433–8.

    Article  CAS  PubMed  Google Scholar 

  34. Rane S, Nada R, Minz M, Sakhuja V, Joshi K. Spectrum of cytomegalovirus-induced renal pathology in renal allograft recipients. Transplant Proc. 2012;44(3):713–6.

    Article  CAS  PubMed  Google Scholar 

  35. Colvin-Adams M, Agnihotri A. Cardiac allograft vasculopathy: current knowledge and future direction. Clin Transpl. 2011;25(2):175–84.

    Article  Google Scholar 

  36. Watkins RR, Lemonovich TL, Razonable RR. Immune response to CMV in solid organ transplant recipients: current concepts and future directions. Expert Rev Clin Immunol. 2012;8(4):383–93.

    Article  CAS  PubMed  Google Scholar 

  37. Jordan SC, Quartel AW, Czer LS, Admon D, Chen G, Fishbein MC, et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation. 1998;66(6):800–5.

    Article  CAS  PubMed  Google Scholar 

  38. Bocrie O, Hussein Aly AA, Guignier F, Funes de la Vega M, Rifle G, Mousson C, et al. Distribution of donor-specific antibodies in the cortex and the medulla of renal transplants with chronic allograft nephropathy. Transpl Immunol. 2007;17(3):227–9.

    Article  CAS  PubMed  Google Scholar 

  39. Nath DS, Ilias Basha H, Tiriveedhi V, Alur C, Phelan D, Ewald GA, et al. Characterization of immune responses to cardiac self-antigens myosin and vimentin in human cardiac allograft recipients with antibody-mediated rejection and cardiac allograft vasculopathy. J Heart Lung Transplant. 2010;29(11):1277–85.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Smith JD, Brunner VM, Jigjidsuren S, Hamour IM, McCormack AM, Banner NR, et al. Lack of effect of MICA antibodies on graft survival following heart transplantation. Am J Transplant. 2009;9(8):1912–9.

    Article  CAS  PubMed  Google Scholar 

  41. Nace G, Evankovich J, Eid R, Tsung A. Dendritic cells and damage-associated molecular patterns: endogenous danger signals linking innate and adaptive immunity. J Innate Immun. 2012;4(1):6–15.

    Article  CAS  PubMed  Google Scholar 

  42. Itescu S, Schuster M, Burke E, Ankersmit J, Kocher A, Deng M, et al. Immunobiologic consequences of assist devices. Cardiol Clin. 2003;21(1):119–33 ix-x.

    Article  PubMed  Google Scholar 

  43. Andrade CF, Waddell TK, Keshavjee S, Liu M. Innate immunity and organ transplantation: the potential role of toll-like receptors. Am J Transplant. 2005;5(5):969–75.

    Article  CAS  PubMed  Google Scholar 

  44. Wyburn KR, Jose MD, Wu H, Atkins RC, Chadban SJ. The role of macrophages in allograft rejection. Transplantation. 2005;80(12):1641–7.

    Article  PubMed  Google Scholar 

  45. Land WG. Innate immunity-mediated allograft rejection and strategies to prevent it. Transplant Proc. 2007;39(3):667–72.

    Article  CAS  PubMed  Google Scholar 

  46. Lakkis FG, Sayegh MH. Memory T cells: a hurdle to immunologic tolerance. J Am Soc Nephrol. 2003;14(9):2402–10.

    Article  PubMed  Google Scholar 

  47. Murata K, Baldwin 3rd WM. Mechanisms of complement activation, C4d deposition, and their contribution to the pathogenesis of antibody-mediated rejection. Transplant Rev (Orlando). 2009;23(3):139–50.

    Article  Google Scholar 

  48. Pietra BA. Transplantation immunology 2003: simplified approach. Pediatr Clin N Am. 2003;50(6):1233–59.

    Article  Google Scholar 

  49. Wood KJ, Bushell A, Hester J. Regulatory immune cells in transplantation. Nat Rev Immunol. 2012;12(6):417–30.

    Article  CAS  PubMed  Google Scholar 

  50. Wood KJ, Goto R. Mechanisms of rejection: current perspectives. Transplantation. 2012;93(1):1–10.

    Article  PubMed  Google Scholar 

  51. Jordan SC, Toyoda M, Vo AA. Regulation of immunity and inflammation by intravenous immunoglobulin: relevance to solid organ transplantation. Expert Rev Clin Immunol. 2011;7(3):341–8.

    Article  CAS  PubMed  Google Scholar 

  52. Coelho V, Saitovitch D, Kalil J, Silva HM. Rethinking the multiple roles of B cells in organ transplantation. Curr Opin Organ Transplant. 2013;18(1):13–21.

    Article  CAS  PubMed  Google Scholar 

  53. Baldwin 3rd WM, Halushka MK, Valujskikh A, Fairchild RL. B cells in cardiac transplants: from clinical questions to experimental models. Semin Immunol. 2012;24(2):122–30.

    Article  CAS  PubMed  Google Scholar 

  54. Kwun J, Bulut P, Kim E, Dar W, Oh B, Ruhil R, et al. The role of B cells in solid organ transplantation. Semin Immunol. 2012;24(2):96–108.

    Article  CAS  PubMed  Google Scholar 

  55. Barnett N, Dorling A, Mamode N. B cells in renal transplantation: pathological aspects and therapeutic interventions. Nephrol Dial Transplant. 2011;26(3):767–74.

    Article  CAS  PubMed  Google Scholar 

  56. Nair N, Ball T, Uber PA, Mehra MR. Current and future challenges in therapy for antibody-mediated rejection. J Heart Lung Transplant. 2011;30(6):612–7.

    Article  PubMed  Google Scholar 

  57. Gareau A, Hirsch GM, Lee TD, Nashan B. Contribution of B cells and antibody to cardiac allograft vasculopathy. Transplantation. 2009;88(4):470–7.

    Article  CAS  PubMed  Google Scholar 

  58. Pratt JR, Basheer SA, Sacks SH. Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med. 2002;8(6):582–7.

    Article  CAS  PubMed  Google Scholar 

  59. Pober JS, Tellides G. Participation of blood vessel cells in human adaptive immune responses. Trends Immunol. 2012;33(1):49–57.

    Article  CAS  PubMed  Google Scholar 

  60. Rothermel AL, Wang Y, Schechner J, Mook-Kanamori B, Aird WC, Pober JS, et al. Endothelial cells present antigens in vivo. BMC Immunol. 2004;5:5.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Goes N, Urmson J, Hobart M, Halloran PF. The unique role of interferon-gamma in the regulation of MHC expression on arterial endothelium. Transplantation. 1996;62(12):1889–94.

    Article  CAS  PubMed  Google Scholar 

  62. Kirk AD, Morrell CN, Baldwin 3rd WM. Platelets influence vascularized organ transplants from start to finish. Am J Transplant. 2009;9(1):14–22.

    Article  CAS  PubMed  Google Scholar 

  63. Charafeddine AH, Kim EJ, Maynard DM, Yi H, Weaver TA, Gunay-Aygun M, et al. Platelet-derived CD154: ultrastructural localization and clinical correlation in organ transplantation. Am J Transplant. 2012;12(11):3143–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Oikonomopoulou K, Ricklin D, Ward PA, Lambris JD. Interactions between coagulation and complement – their role in inflammation. Semin Immunopathol. 2012;34(1):151–65.

    Article  CAS  PubMed  Google Scholar 

  65. Peerschke EI, Yin W, Ghebrehiwet B. Complement activation on platelets: implications for vascular inflammation and thrombosis. Mol Immunol. 2010;47(13):2170–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Wehner J, Morrell CN, Reynolds T, Rodriguez ER, Baldwin 3rd WM. Antibody and complement in transplant vasculopathy. Circ Res. 2007;100(2):191–203.

    Article  CAS  PubMed  Google Scholar 

  67. Loupy A, Cazes A, Guillemain R, Amrein C, Hedjoudje A, Tible M, et al. Very late heart transplant rejection is associated with microvascular injury, complement deposition and progression to cardiac allograft vasculopathy. Am J Transplant. 2011;11(7):1478–87.

    Article  CAS  PubMed  Google Scholar 

  68. Taylor DO, Yowell RL, Kfoury AG, Hammond EH, Renlund DG. Allograft coronary artery disease: clinical correlations with circulating anti-HLA antibodies and the immunohistopathologic pattern of vascular rejection. J Heart Lung Transplant. 2000;19(6):518–21.

    Article  CAS  PubMed  Google Scholar 

  69. Tan CD, Sokos GG, Pidwell DJ, Smedira NG, Gonzalez-Stawinski GV, Taylor DO, et al. Correlation of donor-specific antibodies, complement and its regulators with graft dysfunction in cardiac antibody-mediated rejection. Am J Transplant. 2009;9(9):2075–84.

    Article  CAS  PubMed  Google Scholar 

  70. Billingham ME, Cary NR, Hammond ME, Kemnitz J, Marboe C, McCallister HA, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. J Heat Transf. 1990;9(6):587–93.

    CAS  Google Scholar 

  71. Hammond ME, Stehlik J, Snow G, Renlund DG, Seaman J, Dabbas B, et al. Utility of histologic parameters in screening for antibody-mediated rejection of the cardiac allograft: a study of 3,170 biopsies. J Heart Lung Transplant. 2005;24(12):2015–21.

    Article  PubMed  Google Scholar 

  72. Fedrigo M, Gambino A, Benazzi E, Poli F, Frigo AC, Tona F, et al. Role of morphologic parameters on endomyocardial biopsy to detect sub-clinical antibody-mediated rejection in heart transplantation. J Heart Lung Transplant. 2011;30(12):1381–8.

    Article  PubMed  Google Scholar 

  73. Fishbein GA, Fishbein MC. Morphologic and immunohistochemical findings in antibody-mediated rejection of the cardiac allograft. Hum Immunol. 2012;73(12):1213–7.

    Article  CAS  PubMed  Google Scholar 

  74. Chantranuwat C, Qiao JH, Kobashigawa J, Hong L, Shintaku P, Fishbein MC. Immunoperoxidase staining for C4d on paraffin-embedded tissue in cardiac allograft endomyocardial biopsies: comparison to frozen tissue immunofluorescence. Appl Immunohistochem Mol Morphol. 2004;12(2):166–71.

    Article  PubMed  Google Scholar 

  75. Angelini A, Andersen CB, Bartoloni G, Black F, Bishop P, Doran H, et al. A web-based pilot study of inter-pathologist reproducibility using the ISHLT 2004 working formulation for biopsy diagnosis of cardiac allograft rejection: the European experience. J Heart Lung Transplant. 2011;30(11):1214–20.

    Article  PubMed  Google Scholar 

  76. Labarrere CA, Nelson DR, Park JW. Pathologic markers of allograft arteriopathy: insight into the pathophysiology of cardiac allograft chronic rejection. Curr Opin Cardiol. 2001;16(2):110–7.

    Article  CAS  PubMed  Google Scholar 

  77. Crespo-Leiro MG, Veiga-Barreiro A, Domenech N, Paniagua MJ, Pinon P, Gonzalez-Cuesta M, et al. Humoral heart rejection (severe allograft dysfunction with no signs of cellular rejection or ischemia): incidence, management, and the value of C4d for diagnosis. Am J Transplant. 2005;5(10):2560–4.

    Article  CAS  PubMed  Google Scholar 

  78. Ning Q, Sun Y, Han M, Zhang L, Zhu C, Zhang W, Guo H, Li J, Yan W, Gong F, Chen Z, He W, Koscik C, Smith R, Gorczynski R, Levy G, Luo X. Role of fibrinogen-like protein 2 prothrombinase/fibroleukin in experimental and human allograft rejection. J Immunol. 2005 Jun 1;174(11):7403–11.

    Google Scholar 

  79. Halloran PF, de Freitas DG, Einecke G, Famulski KS, Hidalgo LG, Mengel M, et al. The molecular phenotype of kidney transplants. Am J Transplant. 2010;10(10):2215–22.

    Article  CAS  PubMed  Google Scholar 

  80. Einecke G, Sis B, Reeve J, Mengel M, Campbell PM, Hidalgo LG, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant. 2009;9(11):2520–31.

    Article  CAS  PubMed  Google Scholar 

  81. Sis B, Halloran PF. Endothelial transcripts uncover a previously unknown phenotype: C4d-negative antibody-mediated rejection. Curr Opin Organ Transplant. 2010;15(1):42–8.

    Article  PubMed  Google Scholar 

  82. Mengel M, Sis B, Kim D, Chang J, Famulski KS, Hidalgo LG, et al. The molecular phenotype of heart transplant biopsies: relationship to histopathological and clinical variables. Am J Transplant. 2010;10(9):2105–15.

    Article  CAS  PubMed  Google Scholar 

  83. Freue GV, Sasaki M, Meredith A, Gunther OP, Bergman A, Takhar M, et al. Proteomic signatures in plasma during early acute renal allograft rejection. Mol Cell Proteomics. 2010;9(9):1954–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Kfoury AG, Hammond ME, Snow GL, Stehlik J, Reid BB, Long JW, et al. Early screening for antibody-mediated rejection in heart transplant recipients. J Heart Lung Transplant. 2007;26(12):1264–9.

    Article  PubMed  Google Scholar 

  85. Almuti K, Haythe J, Dwyer E, Itescu S, Burke E, Green P, et al. The changing pattern of humoral rejection in cardiac transplant recipients. Transplantation. 2007;84(4):498–503.

    Article  PubMed  Google Scholar 

  86. Fishbein MC, Kobashigawa J. Biopsy-negative cardiac transplant rejection: etiology, diagnosis, and therapy. Curr Opin Cardiol. 2004;19(2):166–9.

    Article  PubMed  Google Scholar 

  87. Kfoury AG, Snow GL, Budge D, Alharethi RA, Stehlik J, Everitt MD, et al. A longitudinal study of the course of asymptomatic antibody-mediated rejection in heart transplantation. J Heart Lung Transplant. 2012;31(1):46–51.

    Article  PubMed  Google Scholar 

  88. Hodges AM, Lyster H, McDermott A, Rice AJ, Smith JD, Rose ML, et al. Late antibody-mediated rejection after heart transplantation following the development of de novo donor-specific human leukocyte antigen antibody. Transplantation. 2012;93(6):650–6.

    CAS  PubMed  Google Scholar 

  89. Hammond EH, Yowell RL, Price GD, Menlove RL, Olsen SL, O’Connell JB, et al. Vascular rejection and its relationship to allograft coronary artery disease. J Heart Lung Transplant. 1992;11(3 Pt 2):S111–9.

    CAS  PubMed  Google Scholar 

  90. Garrett Jr HE, Duvall-Seaman D, Helsley B, Groshart K. Treatment of vascular rejection with rituximab in cardiac transplantation. J Heart Lung Transplant. 2005;24(9):1337–42.

    Article  PubMed  Google Scholar 

  91. Gill EA, Borrego C, Bray BE, Renlund DG, Hammond EH, Gilbert EM. Left ventricular mass increases during cardiac allograft vascular rejection. J Am Coll Cardiol. 1995;25(4):922–6.

    Article  CAS  PubMed  Google Scholar 

  92. Kfoury AG, Hammond ME, Snow GL, Drakos SG, Stehlik J, Fisher PW, et al. Cardiovascular mortality among heart transplant recipients with asymptomatic antibody-mediated or stable mixed cellular and antibody-mediated rejection. J Heart Lung Transplant. 2009;28(8):781–4.

    Article  PubMed  Google Scholar 

  93. Budge D, Khan F, Hammond M, Nilson Z, Stehlik J, Alharethi R, et al. Safety and Outcomes with Newer Treatment Strategies for Cardiac Antibody-mediated Rejection: Still in the Woods. J Heart Lung Transplant. 2010;29(2S):S42.

    Article  Google Scholar 

  94. Costanzo MR, Dipchand A, Starling R, Anderson A, Chan M, Desai S, et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010;29(8):914–56.

    Article  PubMed  Google Scholar 

  95. Clatworthy MR. Targeting B cells and antibody in transplantation. Am J Transplant. 2011;11(7):1359–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Carrier M, White M, Perrault LP, Pelletier GB, Pellerin M, Robitaille D, et al. A 10-year experience with intravenous thymoglobuline in induction of immunosuppression following heart transplantation. J Heart Lung Transplant. 1999;18(12):1218–23.

    Article  CAS  PubMed  Google Scholar 

  97. Goland S, Czer LS, Coleman B, De Robertis MA, Mirocha J, Zivari K, et al. Induction therapy with thymoglobulin after heart transplantation: impact of therapy duration on lymphocyte depletion and recovery, rejection, and cytomegalovirus infection rates. J Heart Lung Transplant. 2008;27(10):1115–21.

    Article  PubMed  Google Scholar 

  98. Yamani MH, Taylor DO, Czerr J, Haire C, Kring R, Zhou L, et al. Thymoglobulin induction and steroid avoidance in cardiac transplantation: results of a prospective, randomized, controlled study. Clin Transpl. 2008;22(1):76–81.

    Google Scholar 

  99. Uber PA, Mehra MR. Induction therapy in heart transplantation: is there a role? J Heart Lung Transplant. 2007;26(3):205–9.

    Article  PubMed  Google Scholar 

  100. Cantarovich M, Latter DA, Loertscher R. Treatment of steroid-resistant and recurrent acute cardiac transplant rejection with a short course of antibody therapy. Clin Transpl. 1997;11(4):316–21.

    CAS  Google Scholar 

  101. Zand MS. B-cell activity of polyclonal antithymocyte globulins. Transplantation. 2006;82(11):1387–95.

    Article  CAS  PubMed  Google Scholar 

  102. Zand MS, Vo T, Huggins J, Felgar R, Liesveld J, Pellegrin T, et al. Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation. 2005;79(11):1507–15.

    Article  CAS  PubMed  Google Scholar 

  103. Uber WE, Uber LA, VanBakel AB, Crumbley 3rd AJ, Pereira NL, Ikonomidis JS, et al. CD3 monitoring and thymoglobulin therapy in cardiac transplantation: clinical outcomes and pharmacoeconomic implications. Transplant Proc. 2004;36(10):3245–9.

    Article  CAS  PubMed  Google Scholar 

  104. Krasinskas AM, Kreisel D, Acker MA, Bavaria JE, Pochettino A, Kotloff RM, et al. CD3 monitoring of antithymocyte globulin therapy in thoracic organ transplantation. Transplantation. 2002;73(8):1339–41.

    Article  CAS  PubMed  Google Scholar 

  105. Kobashigawa JA, Miller LW, Russell SD, Ewald GA, Zucker MJ, Goldberg LR, et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant. 2006;6(6):1377–86.

    Article  CAS  PubMed  Google Scholar 

  106. Kim HS, Raskova J, Degiannis D, Raska Jr K. Effects of cyclosporine and rapamycin on immunoglobulin production by preactivated human B cells. Clin Exp Immunol. 1994;96(3):508–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Heidt S, Roelen DL, Eijsink C, van Kooten C, Claas FH, Mulder A. Effects of immunosuppressive drugs on purified human B cells: evidence supporting the use of MMF and rapamycin. Transplantation. 2008;86(9):1292–300.

    Article  CAS  PubMed  Google Scholar 

  108. Keogh A, Richardson M, Ruygrok P, Spratt P, Galbraith A, O’Driscoll G, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation. 2004;110(17):2694–700.

    Article  CAS  PubMed  Google Scholar 

  109. Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantine-von Kaeppler HA, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med. 2003;349(9):847–58.

    Article  CAS  PubMed  Google Scholar 

  110. Mancini D, Pinney S, Burkhoff D, LaManca J, Itescu S, Burke E, et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation. 2003;108(1):48–53.

    Article  CAS  PubMed  Google Scholar 

  111. Tzvetanov I, Spaggiari M, Oberholzer J, Setty S, Stephenson A, Thielke J, et al. Cell population in spleens during antibody-mediated rejection: pathologic and clinical findings. Transplantation. 2012;94(3):255–62.

    Article  CAS  PubMed  Google Scholar 

  112. Tzvetanov I, Spaggiari M, Jeon H, Roca RG, Bhati C, Oberholzer J, et al. The role of splenectomy in the setting of refractory humoral rejection after kidney transplantation. Transplant Proc. 2012;44(5):1254–8.

    Article  CAS  PubMed  Google Scholar 

  113. Locke JE, Zachary AA, Haas M, Melancon JK, Warren DS, Simpkins CE, et al. The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection. Am J Transplant. 2007;7(4):842–6.

    Article  CAS  PubMed  Google Scholar 

  114. Kaplan B, Gangemi A, Thielke J, Oberholzer J, Sankary H, Benedetti E. Successful rescue of refractory, severe antibody mediated rejection with splenectomy. Transplantation. 2007;83(1):99–100.

    Article  PubMed  Google Scholar 

  115. Jirasiritham S, Khunprakant R, Techawathanawanna N, Jirasiritham S, Mavichak V. Treatment of simultaneous acute antibody-mediated rejection and acute cellular rejection with alemtuzumab in kidney transplantation: a case report. Transplant Proc. 2010;42(3):987–9.

    Article  CAS  PubMed  Google Scholar 

  116. van den Hoogen MW, Hesselink DA, van Son WJ, Weimar W, Hilbrands LB. Treatment of steroid-resistant acute renal allograft rejection with alemtuzumab. Am J Transplant. 2013;13(1):192–6.

    Article  PubMed  CAS  Google Scholar 

  117. Fassbinder W, Scheuermann EH, Stutte HJ, Bechstein PB, Fursch A, Ernst W, et al. Improved graft prognosis by treatment of steroid resistant rejections with ATG and plasmapheresis. Proc Eur Dial Transplant Assoc. 1983;20:362–7.

    CAS  PubMed  Google Scholar 

  118. Shah A, Nadasdy T, Arend L, Brennan J, Leong N, Coppage M, et al. Treatment of C4d-positive acute humoral rejection with plasmapheresis and rabbit polyclonal antithymocyte globulin. Transplantation. 2004;77(9):1399–405.

    Article  CAS  PubMed  Google Scholar 

  119. Fehr T, Rusi B, Fischer A, Hopfer H, Wuthrich RP, Gaspert A. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection. Transplantation. 2009;87(12):1837–41.

    Article  CAS  PubMed  Google Scholar 

  120. Vo AA, Peng A, Toyoda M, Kahwaji J, Cao K, Lai CH, et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation. 2010;89(9):1095–102.

    Article  CAS  PubMed  Google Scholar 

  121. Zarkhin V, Chalasani G, Sarwal MM. The yin and yang of B cells in graft rejection and tolerance. Transplant Rev (Orlando). 2010;24(2):67–78.

    Article  Google Scholar 

  122. Aranda Jr JM, Scornik JC, Normann SJ, Lottenberg R, Schofield RS, Pauly DF, et al. Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection: a case report. Transplantation. 2002;73(6):907–10.

    Article  PubMed  Google Scholar 

  123. Garrett Jr HE, Groshart K, Duvall-Seaman D, Combs D, Suggs R. Treatment of humoral rejection with rituximab. Ann Thorac Surg. 2002;74(4):1240–2.

    Article  PubMed  Google Scholar 

  124. Baran DA, Lubitz S, Alvi S, Fallon JT, Kaplan S, Galin I, et al. Refractory humoral cardiac allograft rejection successfully treated with a single dose of rituximab. Transplant Proc. 2004;36(10):3164–6.

    Article  CAS  PubMed  Google Scholar 

  125. Kaczmarek I, Deutsch MA, Sadoni S, Brenner P, Schmauss D, Daebritz SH, et al. Successful management of antibody-mediated cardiac allograft rejection with combined immunoadsorption and anti-CD20 monoclonal antibody treatment: case report and literature review. J Heart Lung Transplant. 2007;26(5):511–5.

    Article  PubMed  Google Scholar 

  126. Vincenti F, Cohen SD, Appel G. Novel B cell therapeutic targets in transplantation and immune-mediated glomerular diseases. Clin J Am Soc Nephrol. 2010;5(1):142–51.

    Article  CAS  PubMed  Google Scholar 

  127. Ostergaard M, Baslund B, Rigby W, Rojkovich B, Jorgensen C, Dawes PT, et al. Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study. Arthritis Rheum. 2010;62(8):2227–38.

    Article  PubMed  CAS  Google Scholar 

  128. Cang S, Mukhi N, Wang K, Liu D. Novel CD20 monoclonal antibodies for lymphoma therapy. J Hematol Oncol. 2012;5:64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  129. Tak PP, Mease PJ, Genovese MC, Kremer J, Haraoui B, Tanaka Y, et al. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial. Arthritis Rheum. 2012;64(2):360–70.

    Article  CAS  PubMed  Google Scholar 

  130. Lulu S, Waubant E. Humoral-targeted immunotherapies in multiple sclerosis. Neurotherapeutics. 2013;10(1):34–43.

    Article  CAS  PubMed  Google Scholar 

  131. Dorner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther. 2006;8(3):R74.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  132. Tedder TF. CD19: a promising B cell target for rheumatoid arthritis. Nat Rev Rheumatol. 2009;5(10):572–7.

    Article  CAS  PubMed  Google Scholar 

  133. Lateef A, Petri M. Biologics in the treatment of systemic lupus erythematosus. Curr Opin Rheumatol. 2010;22(5):504–9.

    Article  PubMed  Google Scholar 

  134. Looney RJ. B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data. Drugs. 2010;70(5):529–40.

    Article  CAS  PubMed  Google Scholar 

  135. Kalunian KC, Davis Jr JC, Merrill JT, Totoritis MC, Wofsy D, Group I-LS. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002;46(12):3251–8.

    Article  CAS  PubMed  Google Scholar 

  136. Boumpas DT, Furie R, Manzi S, Illei GG, Wallace DJ, Balow JE, et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 2003;48(3):719–27.

    Article  CAS  PubMed  Google Scholar 

  137. Kirk AD, Knechtle SJ, Sollinger HE. Preliminary results of the use of humanized anti-CD154 in human renal allotrasnplantation. Am J Transplant. 2001;1(191):suppl 1.

    Google Scholar 

  138. Everly JJ, Walsh RC, Alloway RR, Woodle ES. Proteasome inhibition for antibody-mediated rejection. Curr Opin Organ Transplant. 2009;14(6):662–6.

    Article  PubMed  Google Scholar 

  139. Eckman PM, Thorsgard M, Maurer D, Kim Y, Alloway RR, Woodle ES. Bortezomib for refractory antibody-mediated cardiac allograft rejection. Clin Transpl. 2009:475–8.

    Google Scholar 

  140. Trivedi HL, Terasaki PI, Feroz A, Everly MJ, Vanikar AV, Shankar V, et al. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation. 2009;87(10):1555–61.

    Article  CAS  PubMed  Google Scholar 

  141. Morrow WR, Frazier EA, Mahle WT, Harville TO, Pye SE, Knecht KR, et al. Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients. Transplantation. 2012;93(3):319–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  142. Everly MJ, Terasaki PI, Hopfield J, Trivedi HL, Kaneku H. Protective immunity remains intact after antibody removal by means of proteasome inhibition. Transplantation. 2010;90(12):1493–8.

    Article  CAS  PubMed  Google Scholar 

  143. Grauhan O, Knosalla C, Ewert R, Hummel M, Loebe M, Weng YG, et al. Plasmapheresis and cyclophosphamide in the treatment of humoral rejection after heart transplantation. J Heart Lung Transplant. 2001;20(3):316–21.

    Article  CAS  PubMed  Google Scholar 

  144. Hershko AY, Naparstek Y. Removal of pathogenic autoantibodies by immunoadsorption. Ann N Y Acad Sci. 2005;1051:635–46.

    Article  CAS  PubMed  Google Scholar 

  145. Rummler S, Barz D. Plasma Exchange and Immunoadsorption of Patients with Thoracic Organ Transplantation. Transfus Med Hemother. 2012;39(4):234–40.

    Article  PubMed  PubMed Central  Google Scholar 

  146. Jordan SC, Toyoda M, Vo AA. Intravenous immunoglobulin a natural regulator of immunity and inflammation. Transplantation. 2009;88(1):1–6.

    Article  CAS  PubMed  Google Scholar 

  147. Jordan SC, Toyoda M, Kahwaji J, Vo AA. Clinical aspects of intravenous immunoglobulin use in solid organ transplant recipients. Am J Transplant. 2011;11(2):196–202.

    Article  CAS  PubMed  Google Scholar 

  148. Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol. 2008;26:513–33.

    Article  CAS  PubMed  Google Scholar 

  149. Shehata N, Palda VA, Meyer RM, Blydt-Hansen TD, Campbell P, Cardella C, et al. The use of immunoglobulin therapy for patients undergoing solid organ transplantation: an evidence-based practice guideline. Transfus Med Rev. 2010;24(Suppl 1):S7–S27.

    Article  PubMed  Google Scholar 

  150. Leech SH, Lopez-Cepero M, LeFor WM, DiChiara L, Weston M, Furukawa S, et al. Management of the sensitized cardiac recipient: the use of plasmapheresis and intravenous immunoglobulin. Clin Transpl. 2006;20(4):476–84.

    Article  CAS  Google Scholar 

  151. Vaccaro C, Zhou J, Ober RJ, Ward ES. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol. 2005;23(10):1283–8.

    Article  CAS  PubMed  Google Scholar 

  152. Wang H, Jiang J, Liu W, Kubelik D, Chen G, Gies D, et al. Prevention of acute vascular rejection by a functionally blocking anti-C5 monoclonal antibody combined with cyclosporine. Transplantation. 2005;79(9):1121–7.

    Article  CAS  PubMed  Google Scholar 

  153. Rother RP, Arp J, Jiang J, Ge W, Faas SJ, Liu W, et al. C5 blockade with conventional immunosuppression induces long-term graft survival in presensitized recipients. Am J Transplant. 2008;8(6):1129–42.

    Article  CAS  PubMed  Google Scholar 

  154. Gueler F, Rong S, Gwinner W, Mengel M, Brocker V, Schon S, et al. Complement 5a receptor inhibition improves renal allograft survival. J Am Soc Nephrol. 2008;19(12):2302–12.

    Article  PubMed  PubMed Central  Google Scholar 

  155. Locke JE, Magro CM, Singer AL, Segev DL, Haas M, Hillel AT, et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant. 2009;9(1):231–5.

    Article  CAS  PubMed  Google Scholar 

  156. Stewart ZA, Collins TE, Schlueter AJ, Raife TI, Holanda DG, Nair R, et al. Case report: eculizumab rescue of severe accelerated antibody-mediated rejection after ABO-incompatible kidney transplant. Transplant Proc. 2012;44(10):3033–6.

    Article  CAS  PubMed  Google Scholar 

  157. Gonzalez-Roncero F, Suner M, Bernal G, Cabello V, Toro M, Pereira P, et al. Eculizumab treatment of acute antibody-mediated rejection in renal transplantation: case reports. Transplant Proc. 2012;44(9):2690–4.

    Article  CAS  PubMed  Google Scholar 

  158. Noone D, Al-Matrafi J, Tinckam K, Zipfel PF, Herzenberg AM, Thorner PS, et al. Antibody mediated rejection associated with complement factor h-related protein 3/1 deficiency successfully treated with eculizumab. Am J Transplant. 2012;12(9):2546–53.

    Article  CAS  PubMed  Google Scholar 

  159. De Bosscher K, Vanden Berghe W, Haegeman G. Mechanisms of anti-inflammatory action and of immunosuppression by glucocorticoids: negative interference of activated glucocorticoid receptor with transcription factors. J Neuroimmunol. 2000;109(1):16–22.

    Article  CAS  PubMed  Google Scholar 

  160. Almawi WY, Melemedjian OK, Rieder MJ. An alternate mechanism of glucocorticoid anti-proliferative effect: promotion of a Th2 cytokine-secreting profile. Clin Transpl. 1999;13(5):365–74.

    Article  CAS  Google Scholar 

  161. Hayashi R, Wada H, Ito K, Adcock IM. Effects of glucocorticoids on gene transcription. Eur J Pharmacol. 2004;500(1–3):51–62.

    Article  CAS  PubMed  Google Scholar 

  162. Zhao X, Boenisch O, Yeung M, Mfarrej B, Yang S, Turka LA, et al. Critical role of proinflammatory cytokine IL-6 in allograft rejection and tolerance. Am J Transplant. 2012;12(1):90–101.

    Article  CAS  PubMed  Google Scholar 

  163. Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010;62(2):542–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  164. Hughes PD, Cohney SJ. Modifiers of complement activation for prevention of antibody-mediated injury to allografts. Curr Opin Organ Transplant. 2011;16(4):425–33.

    Article  CAS  PubMed  Google Scholar 

  165. Trivedi HL, Terasaki PI, Feroz A, Vanikar AV, Trivedi VB, Khemchandani SI, et al. Clonal deletion with bortezomib followed by low or no maintenance immunosuppression in renal allograft recipients. Transplantation. 2010;90(2):221–2.

    Article  PubMed  Google Scholar 

  166. Itescu S, Tung TC, Burke EM, Weinberg A, Moazami N, Artrip JH, et al. Preformed IgG antibodies against major histocompatibility complex class II antigens are major risk factors for high-grade cellular rejection in recipients of heart transplantation. Circulation. 1998;98(8):786–93.

    Article  CAS  PubMed  Google Scholar 

  167. Kobashigawa JA, Sabad A, Drinkwater D, Cogert GA, Moriguchi JD, Kawata N, et al. Pretransplant panel reactive-antibody screens. Are they truly a marker for poor outcome after cardiac transplantation? Circulation. 1996;94(9 Suppl):II294–7.

    CAS  PubMed  Google Scholar 

  168. Nwakanma LU, Williams JA, Weiss ES, Russell SD, Baumgartner WA, Conte JV. Influence of pretransplant panel-reactive antibody on outcomes in 8,160 heart transplant recipients in recent era. Ann Thorac Surg. 2007;84(5):1556–62 discussion 62–3.

    Article  PubMed  Google Scholar 

  169. Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, Lai CH, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med. 2008;359(3):242–51.

    Article  CAS  PubMed  Google Scholar 

  170. Kobashigawa J, Mehra M, West L, Kerman R, George J, Rose M, et al. Report from a consensus conference on the sensitized patient awaiting heart transplantation. J Heart Lung Transplant. 2009;28(3):213–25.

    Article  PubMed  Google Scholar 

  171. Patel J, Everly M, Chang D, Kittleson M, Reed E, Kobashigawa J. Reduction of alloantibodies via proteasome inhibition in cardiac transplantation. J Heart Lung Transplant. 2011;30(12):1320–6.

    Article  PubMed  Google Scholar 

  172. Kittleson MM, Kobashigawa JA. Antibody-mediated rejection. Curr Opin Organ Transplant. 2012;17(5):551–7.

    Article  CAS  PubMed  Google Scholar 

  173. Billingham RE, Brent L. Further attempts to transfer transplantation immunity by means of serum. Br J Exp Pathol. 1956;37(6):566–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  174. Makela O, Mitchison NA. The role of cell number and source in adoptive immunity. Immunology. 1965;8(6):539–48.

    CAS  PubMed  PubMed Central  Google Scholar 

  175. Carpenter CB, d’Apice AJ, Abbas AK. The role of antibodies in the rejection and enhancement of organ allografts? 7318. Adv Immunol. 1976;22:1–65.

    Article  CAS  PubMed  Google Scholar 

  176. Tilney NL, Kupiec-Weglinski JW, Heidecke CD, Lear PA, Strom TB. Mechanisms of rejection and prolongation of vascularized organ allografts. Immunol Rev. 1984;77:185–216.

    Article  CAS  PubMed  Google Scholar 

  177. Gerlag PG, Koene RA, Hagemann JF, Wijdeveld PG. Hyperacute rejection of skin allografts in the mouse. Sensitivity of ingrowing skin grafts to the action of alloantibody and rabbit complement. Transplantation. 1975;20(4):308–13.

    Article  CAS  PubMed  Google Scholar 

  178. Jooste SV, Colvin RB, Soper WD, Winn HJ. The vascular bed as the primary target in the destruction of skin grafts by antiserum. I. Resistance of freshly placed xenografts of skin to antiserum. J Exp Med. 1981;154(5):1319–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  179. Feucht HE, Felber E, Gokel MJ, Hillebrand G, Nattermann U, Brockmeyer C, et al. Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. Clin Exp Immunol. 1991;86(3):464–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  180. Collins AB, Schneeberger EE, Pascual MA, Saidman SL, Williams WW, Tolkoff-Rubin N, et al. Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol. 1999;10(10):2208–14.

    CAS  PubMed  Google Scholar 

  181. Minami K, Murata K, Lee CY, Fox-Talbot K, Wasowska BA, Pescovitz MD, et al. C4d deposition and clearance in cardiac transplants correlates with alloantibody levels and rejection in rats. Am J Transplant. 2006;6(5 Pt 1):923–32.

    Article  CAS  PubMed  Google Scholar 

  182. Qian Z, Lee CY, Murata K, Liu J, Fox-Talbot K, Wasowska BA, et al. Antibody and complement mediated injury in transplants following sensitization by allogeneic blood transfusion. Transplantation. 2006;82(7):857–64.

    Article  PubMed  Google Scholar 

  183. Murata K, Fox-Talbot K, Qian Z, Takahashi K, Stahl GL, Baldwin 3rd WM, et al. Synergistic deposition of C4d by complement-activating and non-activating antibodies in cardiac transplants. Am J Transplant. 2007;7(11):2605–14.

    Article  CAS  PubMed  Google Scholar 

  184. Wasowska BA, Qian Z, Cangello DL, Behrens E, Van Tran K, Layton J, et al. Passive transfer of alloantibodies restores acute cardiac rejection in IgKO mice. Transplantation. 2001;71(6):727–36.

    Article  CAS  PubMed  Google Scholar 

  185. Rahimi S, Qian Z, Layton J, Fox-Talbot K, Baldwin 3rd WM, Wasowska BA. Non-complement- and complement-activating antibodies synergize to cause rejection of cardiac allografts. Am J Transplant. 2004;4(3):326–34.

    Article  CAS  PubMed  Google Scholar 

  186. Nozaki T, Amano H, Bickerstaff A, Orosz CG, Novick AC, Tanabe K, et al. Antibody-mediated rejection of cardiac allografts in CCR5-deficient recipients. J Immunol. 2007;179(8):5238–45.

    Article  CAS  PubMed  Google Scholar 

  187. Baldwin 3rd WM, Valujskikh A, Fairchild RL. Antibody-mediated rejection: emergence of animal models to answer clinical questions. Am J Transplant. 2010;10(5):1135–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  188. Zhang X, Reed EF. Effect of antibodies on endothelium. Am J Transplant. 2009;9(11):2459–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  189. Jindra PT, Jin YP, Rozengurt E, Reed EF. HLA class I antibody-mediated endothelial cell proliferation via the mTOR pathway. J Immunol. 2008;180(4):2357–66.

    Article  CAS  PubMed  Google Scholar 

  190. Yamakuchi M, Kirkiles-Smith NC, Ferlito M, Cameron SJ, Bao C, Fox-Talbot K, et al. Antibody to human leukocyte antigen triggers endothelial exocytosis. Proc Natl Acad Sci U S A. 2007;104(4):1301–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  191. Jurcevic S, Ainsworth ME, Pomerance A, Smith JD, Robinson DR, Dunn MJ, et al. Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation. Transplantation. 2001;71(7):886–92.

    Article  CAS  PubMed  Google Scholar 

  192. Mahesh B, Leong HS, McCormack A, Sarathchandra P, Holder A, Rose ML. Autoantibodies to vimentin cause accelerated rejection of cardiac allografts. Am J Pathol. 2007;170(4):1415–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  193. Uehara S, Chase CM, Cornell LD, Madsen JC, Russell PS, Colvin RB. Chronic cardiac transplant arteriopathy in mice: relationship of alloantibody, C4d deposition and neointimal fibrosis. Am J Transplant. 2007;7(1):57–65.

    Article  CAS  PubMed  Google Scholar 

  194. Russell PS, Chase CM, Winn HJ, Colvin RB. Coronary atherosclerosis in transplanted mouse hearts. II. Importance of humoral immunity. J Immunol. 1994;152(10):5135–41.

    CAS  PubMed  Google Scholar 

  195. Delgado JF, Manito N, Segovia J, Almenar L, Arizon JM, Camprecios M, et al. The use of proliferation signal inhibitors in the prevention and treatment of allograft vasculopathy in heart transplantation. Transplant Rev (Orlando). 2009;23(2):69–79.

    Article  Google Scholar 

  196. Jin YP, Korin Y, Zhang X, Jindra PT, Rozengurt E, Reed EF. RNA interference elucidates the role of focal adhesion kinase in HLA class I-mediated focal adhesion complex formation and proliferation in human endothelial cells. J Immunol. 2007;178(12):7911–22.

    Article  CAS  PubMed  Google Scholar 

  197. Hattori T, Shimokawa H, Higashi M, Hiroki J, Mukai Y, Kaibuchi K, et al. Long-term treatment with a specific Rho-kinase inhibitor suppresses cardiac allograft vasculopathy in mice. Circ Res. 2004;94(1):46–52.

    Article  CAS  PubMed  Google Scholar 

  198. Koch CA, Khalpey ZI, Platt JL. Accommodation: preventing injury in transplantation and disease. J Immunol. 2004;172(9):5143–8.

    Article  CAS  PubMed  Google Scholar 

  199. Alexandre GP, Squifflet JP, De Bruyere M, Latinne D, Reding R, Gianello P, et al. Present experiences in a series of 26 ABO-incompatible living donor renal allografts. Transplant Proc. 1987;19(6):4538–42.

    CAS  PubMed  Google Scholar 

  200. Williams JM, Holzknecht ZE, Plummer TB, Lin SS, Brunn GJ, Platt JL. Acute vascular rejection and accommodation: divergent outcomes of the humoral response to organ transplantation. Transplantation. 2004;78(10):1471–8.

    Article  PubMed  Google Scholar 

  201. Soares MP, Brouard S, Smith RN, Bach FH. Heme oxygenase-1, a protective gene that prevents the rejection of transplanted organs. Immunol Rev. 2001;184:275–85.

    Article  CAS  PubMed  Google Scholar 

  202. Tabata T, de Perrot M, Keshavjee S, Liu M, Downey GP, Waddell TK. Accommodation after lung xenografting from hamster to rat. Transplantation. 2003;75(5):607–12.

    Article  CAS  PubMed  Google Scholar 

  203. Delikouras A, Hayes M, Malde P, Lechler RI, Dorling A. Nitric oxide-mediated expression of Bcl-2 and Bcl-xl and protection from tumor necrosis factor-alpha-mediated apoptosis in porcine endothelial cells after exposure to low concentrations of xenoreactive natural antibody. Transplantation. 2001;71(5):599–605.

    Article  CAS  PubMed  Google Scholar 

  204. Ding JW, Zhou T, Ma L, Yin D, Shen J, Ding CP, et al. Expression of complement regulatory proteins in accommodated xenografts induced by anti-alpha-Gal IgG1 in a rat-to-mouse model. Am J Transplant. 2008;8(1):32–40.

    CAS  PubMed  Google Scholar 

  205. Jindra PT, Zhang X, Mulder A, Claas F, Veale J, Jin YP, et al. Anti-HLA antibodies can induce endothelial cell survival or proliferation depending on their concentration. Transplantation. 2006;82(1 Suppl):S33–5.

    Article  CAS  PubMed  Google Scholar 

  206. Colvin RB, Smith RN. Antibody-mediated organ-allograft rejection. Nat Rev Immunol. 2005;5(10):807–17.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Intermountain Medical Center (UTAH Cardiac Transplant Program), Intermountain Heart Institute, 5121 South Cottonwood Street, Salt Lake City, USA

    Abdallah Georges Kfoury MD, FACC, Deborah Budge MD & M. Elizabeth H. Hammond MD

  2. University of Utah School of Medicine, Salt Lake City, USA

    Abdallah Georges Kfoury MD, FACC & M. Elizabeth H. Hammond MD

  3. Intermountain Healthcare, Primary Care Clinical Program, Institute for Health Care Delivery Research, 36 South State Street, Salt Lake City, UT, 84111, USA

    Kimberly D. Brunisholz PhDc, MST

Authors
  1. Abdallah Georges Kfoury MD, FACC
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Deborah Budge MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kimberly D. Brunisholz PhDc, MST
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Elizabeth H. Hammond MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Abdallah Georges Kfoury MD, FACC .

Editor information

Editors and Affiliations

  1. Division of Cardiology, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA

    Howard Eisen

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer-Verlag London

About this chapter

Cite this chapter

Kfoury, A.G., Budge, D., Brunisholz, K.D., Hammond, M.E.H. (2017). Antibody-Mediated Rejection. In: Eisen, H. (eds) Heart Failure. Springer, London. https://doi.org/10.1007/978-1-4471-4219-5_22

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-4219-5_22

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-4218-8

  • Online ISBN: 978-1-4471-4219-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation